Now showing items 1-2 of 2

    • Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model 

      Kim, Eugene; Tunset, Hanna Maja; Cebulla, Jana; Vettukattil, Muhammad Riyas; Helgesen, Heidi; Feuerherm, Astrid Jullumstrø; Engebråten, Olav; Mælandsmo, Gunhild; Johansen, Berit; Moestue, Siver Andreas (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-03-07)
      <b>Background</b> <br> Group IVA cytosolic phospholipase A2 (cPLA2α) plays an important role in tumorigenesis and angiogenesis. It is overexpressed in basal-like breast cancer (BLBC), which is aggressive and usually triple-negative, making it unresponsive to current targeted therapies. Here, we evaluated the anti-angiogenic effects of a specific cPLA2α inhibitor, AVX235, in a patient-derived ...
    • Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer 

      Grinde, Maria Tunset; Hilmarsdòttir, Bylgja; Tunset, Hanna Maja; Henriksen, Ida Marie; Kim, Jana; Haugen, Mads Haugland; Rye, Morten Beck; Mælandsmo, Gunhild Mari; Moestue, Siver Andreas (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-05-14)
      <p><i>Introduction - </i>Glutaminase inhibitors target cancer cells by blocking the conversion of glutamine to glutamate, thereby potentially interfering with anaplerosis and synthesis of amino acids and glutathione. The drug CB-839 has shown promising effects in preclinical experiments and is currently undergoing clinical trials in several human malignancies, including triple-negative breast cancer ...